Search results
...Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory...
Morningstar· 3 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy
MedPage Today· 7 days agoOnly one of 724 patients treated with chimeric antigen receptor (CAR) T-cell therapy for B-cell ...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 6 days agoIn one study, Pfizer's Seagen-acquired drug, Adcetris, reduced the risk of death by 37% for patients...
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Zacks via Yahoo Finance· 9 hours agoFDA, however, issued complete response letters (CRLs) for its BLA for odronextamab. The BLA is...
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
Zacks via Yahoo Finance· 1 day agoRoche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory...
Atezolizumab Consolidation Impresses in High-Risk DLBCL
MedPage Today· 5 days agoPostchemotherapy consolidation with atezolizumab (Tecentriq) led to a surprisingly high 2-year...
EHA 2024: Brukinsa/Venclexta for CLL/SLL lacks control arm in SEQUOIA trial
Clinical Trials Arena via Yahoo Finance· 1 day agoAlthough several targeted therapies such as Bruton tyrosine kinase (BTK) inhibitors and B cell ...
EHA 2024: Roche’s Columvi competes in BiTE battle with positive results in DLBCL
Pharmaceutical Technology via Yahoo Finance· 2 days agoBased on the latest STARGLO trial results, there is potential to extend Columvi into earlier lines...
Roche’s Columvi offers extended survival in Phase III DLBCL trial
Clinical Trials Arena via Yahoo Finance· 2 days agoRoche has reported findings from the Phase III STARGLO clinical trial where Columvi, in combination...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 2 days agoFate Therapeutics is also advancing its Phase I study of ADR-armed FT522 (CD19 CAR-INK) for patients...